Linden Capital Partners has added Ron Labrum to its team as an operating partner. Previously, Labrum was chief executive of Fenwal.
CHICAGO, IL – December 11, 2014 – Linden Capital Partners, a Chicago-based private equity firm focused exclusively on healthcare, today announced the addition of Ron Labrum as an Operating Partner. Mr. Labrum will be the lead Operating Partner for Linden’s Distribution efforts and expands its Medical Products team. Mr. Labrum was most recently Chief Executive of Fenwal Inc., a $630mm device manufacturer focused on blood technologies divested from Baxter International.
“We are excited to add Ron to our growing and talented team of Operating Partners,” said Linden Partner Bill Drehkoff. “In addition to distribution, Ron’s sector expertise is broad and overlapping with several areas of focus for Linden, and we look forward to working with him.”
Mr. Labrum started his career at American Hospital Supply and spent the next thirty years in leadership positions at Baxter International, Allegiance Healthcare, and Cardinal Health, including serving as President of Allegiance Healthcare.
“The Linden platform is an ideal opportunity for me to apply years of experience in leadership and governance,” noted Mr. Labrum. “Through my interaction with Linden, I’ve seen how the fit between my interests and Linden’s investment strategies align so well.”
Mr. Labrum serves on the boards of Wright Medical, Aptalis, Suture Express, and Ortho-Clinical Diagnostics. He holds a Bachelor of Business Administration from Utah State University.
About Linden Capital Partners
Linden Capital Partners is Chicago-based private equity firm focused exclusively on leveraged buyouts in the healthcare and life sciences industries. Linden’s strategy is based upon three elements: i) healthcare and life science industry specialization, ii) integrated private equity and operating expertise, and iii) strategic relationships with large corporations. Linden invests in middle market platforms in the medical products, specialty distribution, pharmaceutical, and services segments of healthcare.